Table 3.
Outcomes After Open-Label Treatment Selection by Vulvar Vestibular Clinical Trial Participants During Weeks 13 to 52 Postrandomization
| Open-Label Treatment Choices | n (%) | Tampon Test | Sex Pain | Cotton Swab Test–Vestibule | Algesiometer | McGill Short Form Total | Neuropathic Pain Scale Total |
|---|---|---|---|---|---|---|---|
| Desipramine+lidocaine | 35 (27) | − 0.9 (1.2) | − 0.1 (2.4) | − 3.8 (8.1) | 4.4 (10.6) | − 0.9 (4.2) | − 6.3 (13.4) |
| Desipramine only | 9(7) | − 0.4 (0.7) | − 0.9 (1.8) | −4.9 (9.1) | 3.0 (10.3) | −2.0 (3.7) | − 7.7 (17.0) |
| Lidocaine only | 24 (18) | − 0.5 (0.9) | − 0.2 (2.3) | −4.5 (7.1) | 1.7 (9.5) | − 1.5 (7.8) | − 4.4 (19.6) |
| Gabapentin+lidocaine | 10 (8) | 0.8 (3.7) | 1.0 (4.3) | 3.3 (12.1)* | 3.9 (8.7) | 0.3 (7.1) | − 2.3 (17.9) |
| Gabapentin only | 5 (4) | − 1.2 (1.1) | − 1.9 (3.5) | − 6.6 (4.4) | 9.8 (11.7) | − 3.6 (5.3) | − 2.8 (23.5) |
| Surgery during trial | 12 (9) | − 1.3 (2.6) | − 0.4 (1.5) | − 9.2 (10.9)† | 9.2 (10.9) | − 5.4 (6.5)‡ | − 14.8 (20.3) |
| None | 16 (12) | 0.2 (2.2) | 1.3 (2.5) | −0.2 (9.3) | 1.1 (11.1) | − 1.4 (5.6) | −4.1 (20.6) |
| Other | 1 (1) | ||||||
| Unknown | 20 (15) | ||||||
| Total participants | 132 |
Data are mean (standard deviation) unless otherwise specified.
*
t= −2.39; P=.02.
†
t= −2.27; P=.03.
‡
t=− 2.25; P=.03.